PRPH News and Press, ProPhase Labs Inc. From 01/04/24

2024-01-04 10:19:21 ET More on ProPhase Labs ProPhase Labs, Inc. (PRPH) Q3 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on ProPhase Labs Historical earnings data for ProPhase Labs Financial information for ProPhase Labs For furthe...

Company also plans to commercialize its BE-Smart Esophageal Cancer Test in 2024 Company announces the hiring of long-time industry veteran Jed Latkin as COO to help build and manage this growth Garden City, NY, Jan. 04, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: P...

2023-11-09 16:11:02 ET ProPhase Labs, Inc. (PRPH) Q3 2023 Earnings Conference Call November 9, 2023, 11:00 AM ET Company Participants Ted Karkus - Chairman and CEO Conference Call Participants Adam Waldo - Lismore Partners Yi Chen - H.C. Wainwright Hu...

Company sees significant momentum in Pharmaloz, Nebula Genomics and ProPhase BioPharma Pharmaloz Manufacturing plans on track to increase capacity from $10 million to over $75 million in 2024 Indications of demand for entire planned capacity expansion Nebula Genomics opens n...

Histogen Inc. (HSTO) is expected to report for Q3 2023 News Corporation (NWSA) is expected to report $0.13 for Q1 2024 TORM plc (TRMD) is expected to report for Q3 2023 Blink Charging Co. (BLNK) is expected to report $-0.47 for Q3 2023 Nuvalent Inc. (NUVL) is expected to report $-...

ProPhase Labs Inc. (PRPH) is expected to report $-0.2 for Q3 2023

2023-11-08 12:03:07 ET More on ProPhase Labs Seeking Alpha’s Quant Rating on ProPhase Labs Historical earnings data for ProPhase Labs Financial information for ProPhase Labs For further details see: ProPhase Labs Q3 2023 Earnings Preview

GARDEN CITY, NY, Nov. 02, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a next generation biotech, genomics, therapeutics and diagnostics company, will hold a conference call on Thursday, November 9, 2023, at 11:00 a.m. Eastern time to discuss its results for the third quart...

Pharmaloz plan is to build capacity with a goal to attain a revenue run-rate of $60 to $80 million by year-end 2024, with 20-25% pre-tax net margins and a goal for additional growth thereafter. Garden City, NY, Oct. 17, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a next gen...

ROCHESTER, N.Y., Oct. 12, 2023 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS), a multinational company operating nine (9) diversified business lines developed through strategic acquisitions to build shareholder value through periodic spinoffs to its shareholders, announced today that it has i...